Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease LHGDN [Expression of tumor necrosis factor-alpha and nuclear factor-kappa B in childhood ulcerative colitis]. 14731353 2003
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE We investigate the association between TNF promoter polymorphisms and susceptibility to ulcerative colitis (UC) in the Chinese Han ethnic population. 16863613 2006
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We further demonstrated that GSK2256294, a clinical EPHX2i, reduced the production of IL2, IL12p70, IL10 and TNFα in both ulcerative colitis and Crohn's disease patient-derived explant cultures. 31002701 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE We evaluated expression of Tumor Necrosis Factor Alpha Induced Protein3 (TNFAIP3), the inhibitor of NFκB activation and its associated partners ITCH, RNF11 and Tax1BP1 in inflamed mucosa of UC patients. 28842689 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We conducted an observational study of 47 consecutive patients with Crohn's disease (CD; n = 31) or ulcerative colitis (UC; n = 16) who had not responded to 2 previous treatment regimens with antagonists of tumor necrosis factor and were starting therapy with vedolizumab at 2 hospitals in France, from June 2014 through April 2016. 27890854 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We collected information on 39 patients with an active steroid-refractory UC (31 with active severe UC and 36 failed by treatment with a tumor necrosis factor antagonist) who received a calcineurin inhibitor as induction therapy along with vedolizumab as maintenance therapy. 30213584 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE We aimed to investigate the impact of the single nucleotide polymorphisms of rs34436714 of the NOD-like receptor protein 12 gene on the production of tumor necrosis factor-alpha (TNFα) in patients with inflammatory bowel disease (IBD)In a matched case-control study 90 patients with IBD, 56 with Crohn disease (CD) and 34 with ulcerative colitis, were genotyped and compared to 98 healthy comparators matched for age and gender. 31169706 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We aimed to compare the treatment persistence rates of infliximab versus adalimumab as first- and second-line tumor necrosis factor antagonists (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for withdrawal in UC patients. 30329067 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE Vedolizumab is efficacious as induction and maintenance therapy in UC patients who are naïve or refractory to tumor necrosis factor antagonists. 28276855 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE Variation was observed between the ulcerative colitis study group and the control population for the TNF-alpha-308 polymorphism (p= 0.0135). 15223609 2004
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Using a Stanford University database, we queried TNFα inhibitor prescriptions in 8905 patients with an ICD-9 diagnosis of Crohn's disease or ulcerative colitis. 28417241 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Two main points may help physicians to decide when the surgical option may be considered in patients with chronic refractory UC: (1) a first risk stratification can be obtained by analyzing factors at baseline and medical history, including the previous exposure to anti-TNFs; (2) during therapy with biologics, the early assessment (after 12-16 weeks of treatment) of clinical and endoscopic response is a strong predictor of the subsequent risk of colectomy. 30826279 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Twenty-five patients with ulcerative colitis (40% anti-tumor necrosis factor α [TNFα] naive) and 28 patients with Crohn's disease (10.7% anti-TNFα naive, 53.6% having undergone at least one intestinal surgery) were enrolled. 30134234 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014).Surgery for IBD decreased with time. 31252191 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Treatment of the two major forms of IBD, Crohn's disease and ulcerative colitis, involves the reduction of inflammation with toxic immunosuppressive drugs or blocking of the pro-inflammatory effects of tumour necrosis factor-alpha (TNF-alpha) with antibodies. 17207256 2007
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with anti-TNFα agents for diseases other than inflammatory bowel disease (IBD) METHODS: A nationwide cohort study, based on Danish health registries, of all patients who utilised anti-TNFα agents for non-IBD indications. 31267570 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC). 28577692 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE To determine potential associations of interleukin-1 receptor antagonist (IL-1ra), tumour necrosis factor alpha (TNF alpha), and tumour necrosis factor beta (TNF beta) gene polymorphisms with ulcerative colitis or subsets of ulcerative colitis in a Spanish population. 10321759 1999
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC). 30430682 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE To describe the prevalence of serological markers in newly diagnosed treatment-naïve pediatric inflammatory bowel disease (IBD), their utility in differentiating Crohn's disease (CD), ulcerative colitis (UC) and symptomatic non-IBD patients and whether serological markers are associated with early TNF blocker treatment. 27887202 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To date, responsiveness to tumor necrosis factor alpha inhibitors in ulcerative colitis (UC) patients is not predictable. 31782956 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach. 29205406 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE This study suggests that one of the genes responsible for UC may be the TNF gene, or an adjacent gene, and that TNFRSF1B gene polymorphisms contribute greatly to the increased onset risk of CD and to the disease behavior. 11904678 2002
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease LHGDN This study suggests that one of the genes responsible for UC may be the TNF gene, or an adjacent gene, and that TNFRSF1B gene polymorphisms contribute greatly to the increased onset risk of CD and to the disease behavior. 11904678 2002
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE This is the first time that the effect of original CS against UC in mice has been reported and it is through promoting dominant intestinal microflora such as <i>Blautia</i>, mitigating intestinal microflora dysbiosis, and regulating the expressions of TNF-α, claudin-1, occludin, and ZO-1. 31731793 2019